Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians

par Muhammad Afzal, Fahad A. Al-Abbasi, Muhammad Shahid Nadeem, Sultan Alshehri, Mohammed M. Ghoneim, Syed Sarim Imam, Waleed Hassan Almalki, Imran Kazmi
Publié 2021

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

par Perna S, Mainardi M, Astrone P, Gozzer C, Biava A, Bacchio R, Spadaccini D, Solerte SB, Rondanelli M
Publié 2018

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus

par Ahmadieh H, Ghazal N, Azar ST
Publié 2017

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review

par Aurélie Pahud de Mortanges, Dante Salvador Jr., Dante Salvador Jr., Markus Laimer, Taulant Muka, Matthias Wilhelm, Arjola Bano, Arjola Bano
Publié 2021

Is cancer incidence modified by SGLT2 inhibitors?

par Lev M. Berstein
Publié 2019

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

par Simes BC, MacGregor GG
Publié 2019

Empagliflozin: a new strategy for nephroprotection in diabetes

par Anton Ivanovich Korbut, Vadim Valer'evich Klimontov
Publié 2017

Diabetes mellitus associated with the mutation of the ABCC8 gene (MODY 12): features of clinical course and therapy

par Alla K. Ovsyannikova, Oksana D. Rymar, Elena V. Shakhtshneider, Vadim V. Klimontov, Elena A. Koroleva, Mikhail I. Voevoda
Publié 2019

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

par Avgerinos I, Liakos A, Tsapas A, Bekiari E
Publié 2019

Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis

par Clara M. Gomez-Sanchez, MD, Bian X. Wu, MD, Jeffrey E. Gotts, MD, Robert W. Chang, MD
Publié 2021

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

par Steffen Pabel, Nazha Hamdani, Nazha Hamdani, Jagdeep Singh, Samuel Sossalla, Samuel Sossalla
Publié 2021

In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia

par Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska
Publié 2021

Second line therapy in type 2 diabetes: legacy effect activation

par Ekaterina A. Shestakova
Publié 2017

Heart failure in diabetes: From an increased risk to a treatment target

par Eberhard Standl
Publié 2018

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

par Stefan D. Anker
Publié 2019

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages

par Masao Koike, Hitoki Saito, Genta Kohno, Masahiro Takubo, Kentaro Watanabe, Hisamitsu Ishihara
Publié 2021

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach

par Jadwiga Nessler
Publié 2021

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by...

par Kawarasaki S, Sawazaki H, Iijima H, Ng SP, Kwon J, Mohri S, Iwase M, Jheng HF, Takahashi H, Nomura W, Inoue K, Kawada T, Goto T
Publié 2020

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension

par Silvie Hojná, Hana Rauchová, Hana Malínská, Irena Marková, Martina Hüttl, František Papoušek, Michal Behuliak, Denisa Miklánková, Zdeňka Vaňourková, Jan Neckář, Michaela Kadlecová, Petr Kujal, Josef Zicha, Ivana Vaněčková
Publié 2021

Adjunctive therapy for glucose control in patients with type 1 diabetes

par Harris K, Boland C, Meade L, Battise D
Publié 2018